INDGNHealthcare Research, Analytics & Technology
Indegene Ltd — Profit & Loss Statement
₹434.60
-1.77%
Indegene Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.64 Cr | 0.00 | -11.92 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.27 | 0.27 | 0.28 | — |
| Normalized EBITDA | 641.50 Cr | 581.70 Cr | 454.10 Cr | 307.01 Cr | — |
| Total Unusual Items | 0.00 | 2.40 Cr | 0.00 | -42.39 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 2.40 Cr | 0.00 | -42.39 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 406.70 Cr | 336.70 Cr | 266.10 Cr | 164.76 Cr | — |
| Reconciled Depreciation | 80.20 Cr | 76.10 Cr | 59.80 Cr | 33.45 Cr | — |
| EBITDA | 641.50 Cr | 584.10 Cr | 454.10 Cr | 264.62 Cr | — |
| EBIT | 561.30 Cr | 508.00 Cr | 394.30 Cr | 231.17 Cr | — |
| Net Interest Income | -22.00 Cr | -49.40 Cr | -31.30 Cr | -5.16 Cr | — |
| Interest Expense | 22.00 Cr | 49.40 Cr | 31.30 Cr | 4.67 Cr | — |
| Normalized Income | 406.70 Cr | 334.94 Cr | 266.10 Cr | 195.24 Cr | — |
| Net Income From Continuing And Discontinued Operation | 406.70 Cr | 336.70 Cr | 266.10 Cr | 164.76 Cr | — |
| Total Expenses | 2.39K Cr | 2.16K Cr | 1.97K Cr | 1.41K Cr | — |
| Diluted Average Shares | 23.90 Cr | 23.89 Cr | 23.93 Cr | 23.93 Cr | — |
| Basic Average Shares | 23.71 Cr | 23.89 Cr | 23.93 Cr | 23.93 Cr | — |
| Diluted EPS | 17.02 | 14.09 | 11.12 | 6.89 | — |
| Basic EPS | 17.15 | 14.09 | 11.12 | 6.89 | — |
| Diluted NI Availto Com Stockholders | 406.70 Cr | 336.70 Cr | 266.10 Cr | 164.76 Cr | — |
| Net Income Common Stockholders | 406.70 Cr | 336.70 Cr | 266.10 Cr | 164.76 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 406.70 Cr | 336.70 Cr | 266.10 Cr | 164.76 Cr | — |
| Net Income Including Noncontrolling Interests | 406.70 Cr | 336.70 Cr | 266.10 Cr | 162.82 Cr | — |
| Net Income Continuous Operations | 406.70 Cr | 336.70 Cr | 266.10 Cr | 162.82 Cr | — |
| Tax Provision | 132.60 Cr | 121.90 Cr | 96.90 Cr | 63.68 Cr | — |
| Pretax Income | 539.30 Cr | 458.60 Cr | 363.00 Cr | 226.50 Cr | — |
| Other Non Operating Income Expenses | 107.20 Cr | 76.30 Cr | 58.00 Cr | 1.10 Cr | — |
| Special Income Charges | 0.00 | 2.40 Cr | 0.00 | -47.41 Cr | — |
| Net Non Operating Interest Income Expense | -22.00 Cr | -49.40 Cr | -31.30 Cr | -5.16 Cr | — |
| Interest Expense Non Operating | 22.00 Cr | 49.40 Cr | 31.30 Cr | 4.67 Cr | — |
| Operating Income | 454.10 Cr | 429.30 Cr | 336.30 Cr | 253.98 Cr | — |
| Operating Expense | 2.39K Cr | 2.16K Cr | 1.97K Cr | 1.41K Cr | — |
| Other Operating Expenses | 489.80 Cr | 432.60 Cr | 445.20 Cr | 287.13 Cr | — |
| Depreciation And Amortization In Income Statement | 80.20 Cr | 76.10 Cr | 59.80 Cr | 33.45 Cr | — |
| Depreciation Income Statement | 80.20 Cr | 76.10 Cr | 59.80 Cr | 28.99 Cr | — |
| Total Revenue | 2.84K Cr | 2.59K Cr | 2.31K Cr | 1.66K Cr | — |
| Operating Revenue | 2.84K Cr | 2.59K Cr | 2.31K Cr | 1.66K Cr | — |
| Write Off | — | 91.10 Cr | 0.00 | 0.51 Cr | 0.00 |
| Restructuring And Mergern Acquisition | — | -93.50 Cr | 0.00 | 46.90 Cr | -8.24 Cr |
| Interest Income | — | — | 10.30 Cr | 0.80 Cr | 0.89 Cr |
| Rent Expense Supplemental | — | — | 3.97 Cr | 7.30 Cr | 4.75 Cr |
| Minority Interests | — | — | 0.00 | 1.94 Cr | -80000.00 |
| Net Income Discontinuous Operations | — | — | 0.00 | 0.00 | -36.27 Cr |
| Total Other Finance Cost | — | — | 8.04 Cr | 1.29 Cr | 1.45 Cr |
| Interest Income Non Operating | — | — | 10.30 Cr | 0.80 Cr | 0.89 Cr |
| Amortization | — | — | 16.81 Cr | 4.46 Cr | — |
| Selling General And Administration | — | — | 85.81 Cr | 54.46 Cr | 37.24 Cr |
| General And Administrative Expense | — | — | 85.81 Cr | 54.46 Cr | 37.24 Cr |
| Rent And Landing Fees | — | — | 3.97 Cr | 7.30 Cr | 4.75 Cr |
| Other Special Charges | — | — | — | — | -36.61 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Indegene Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.